Left Atrial Appendage Closure With WATCHMAN FLX Device in Recurrent Gastrointestinal Bleeding: The GI-FLX Registry
Trial Summary
What is the purpose of this trial?
The GI-FLX Registry is intended to create a registry of patients with a history of Atrial Fibrillation (AF) and Gastrointestinal (GI) bleed who will receive Left Atrial Appendage Closure (LAAC) with WATCHMAN FLX device and compare to patients with AF and GI bleed who do not have LAAC. The GI-FLX Registry will be a multi-center, non-randomized registry. Approximately 250 prospective patients will be enrolled at all 4 sites. Historical cohort of 250 patients after propensity score matching with WATCHMAN-FLX arm will be included in the final analysis.
Research Team
Dhanunjaya Lakkireddy, MD
Principal Investigator
Kansas City Heart Rhythm Institute
Eligibility Criteria
Inclusion Criteria
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kansas City Heart Rhythm Research Foundation
Lead Sponsor
Texas Cardiac Arrythmia Institute, Austin, Texas
Collaborator
Centennial Medical Center, Nashville, Tennessee
Collaborator
Kansas City Heart Rhythm Institute, Overland Park, Kansas
Collaborator
Los Robles Health System, Los Robles, California
Collaborator